SUDAFED SINUS NIGHTTIME OTC
Generic Name and Formulations:
Triprolidine HCl 2.5mg, pseudoephedrine HCl 60mg; per tab.
McNeil Consumer Healthcare
Indications for SUDAFED SINUS NIGHTTIME:
Rhinorrhea, nasal congestion, allergy symptoms.
1 tab every 4–6 hours as needed; max 4 doses/24hrs.
<6yrs: individualize. 6–11yrs: ½ tab every 4–6 hours as needed; max 4 doses/24hrs.
Within 14 days of MAOIs.
Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders.
Hypertensive crisis with MAOIs. β-blockers may increase pressor response of sympathomimetics. Alcohol, other CNS depressants potentiated. Antagonizes antihypertensives.
Antihistamine + sympathomimetic.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Expert Roundtable: AHA Update on Dietary Fat Intake and CVD Risk
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation